Paroxysmal atrial fibrillation: A common but neglected entity

Archives of Internal Medicine

Volumn 156, Issue 4, 1996, Pages 362-367

  Aboaf, Alan P ^a   Wolf, Phillip S ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DIGOXIN; ESMOLOL; FLECAINIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL; WARFARIN;

ANTICOAGULANT THERAPY; ARTIFICIAL HEART PACEMAKER; CARDIOVERSION; DRUG EFFICACY; EMBOLISM; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART RATE; HUMAN; PRIORITY JOURNAL; RADIOFREQUENCY; REVIEW; SINUS RHYTHM; STROKE;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; HEART ATRIA; HUMANS; TACHYCARDIA, PAROXYSMAL;

EID: 0030047750     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.4.362     Document Type: Review

References (55)

1. Godtfredsen J Atrial Fibrillation, Etiology, Course, and Prognosis: A Follow-up Study of 1212 Cases. Copenhagen, Denmark University of Copenhagen; 1975. Thesis.
2. Takahashi N, Seki A, Imataka K, Fujii J Clinical features of paroxysmal atrial fibrillation. Jpn Heart J. 1981;22:143-149
3. Parkinson J, Campbell M. Paroxysmal auricular fibrillation: a record of 200 patients. Q J Med. 1930;24.67-92.
4. Davidson E, Weinberger I, Rotenberg Z, Fuchs J, Agmon J Atrial fibrillation. Arch Intern Med. 1989;149:457-459.
5. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett ELC. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia Circulation. 1994;89:224-227.
6. Suttorp MJ, Kingma JH, Koomen EM, Hof AV, Tijssen JGP, Lie KI. Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol 1993;71 710-713.
7. Clementy J, Dulhoste MN, Laiter C, Denjoy I, Dos Santos P. Flecainide acetate in the prevention of paroxysmal atrial fibrillation a nine-month follow-up of more than 500 patients. Am J Cardiol. 1992;70(suppl):44A-49A
8. Stroke Prevention in Atrial Fibrillation Investigators Stroke Prevention in Atrial Fibrillation Study: final results Circulation. 1991;84:527-539.
9. Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and the risk of stroke: The Framingham Study. Neurology. 1978;28:973-977
10. Kannel WB, Abbott RD, Savage DD. Coronary heart disease and atrial fibrillation: The Framingham Study Am Heart J 1983;106:389-396.
11. Petersen P, Godtfredsen J Embolic complications in paroxysmal atrial fibrillation Stroke. 1986; 17:622-625
12. Treseder AS, Sastry BSD, Thomas TPL, Yates MA, Pathy MSJ. Atrial fibrillation and stroke in hospitalized elderly patients. Age Ageing. 1986; 15:89-92
13. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511
14. Atrial Fibrillation Investigators. Risk factors for stroke efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994,154:1449-1457
15. Wolf PA, Kannel WB, McGee DL, Meeks SL, Bharucha NE, McNamara PM. Duration of atrial fibrillation and imminence of stroke: The Framingham Study Stroke 1983;14:664-667.
16. Takahashi N, Imataka K, Seki A, Fujii J. Left atrial enlargement in patients with paroxysmal atrial fibrillation Jpn Heart J. 1982;23:677-683.
17. Villecco AS, Pilati G, Bianchi G, Zanardi L Left atrial size in paroxysmal atrial fibrillation. Cardiology. 1992;80:89-93.
18. Corbalán R, Arriagada D, Braun S et al. Risk factors for systemic embolism in patients with paroxysmal atrial fibrillation Am Heart J. 1992;124:149-153
19. Godtfredsen J, Egeblad H, Berning J. Echocardiography in lone atrial fibrillation. Acta Med Scand. 1983;213 111-113
20. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. N Engl J Med 1987;317:669-674
21. Close JB, Evans DW, Bailey SM. Persistent lone atrial fibrillation, its prognosis after clinical diagnosis. J R Coll Gen Pract. 1979,29.547-549.
22. Davidson E, Rotenberg Z, Weinberger I, Fuchs J, Agmon J Diagnosis and characteristics of lone atrial fibrillation. Chest. 1989;95:1048-1050.
23. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation JAMA. 1985,254 3449-3453.
24. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med. 1991,114:573-575.
25. Galun E, Flugelman MY, Glickson M, Eliakin M Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest. 1991;99:1038-1040.
26. Falk RH, Podrid PJ. Atrial Fibrillation: Mechanisms and Management New York NY: Raven Press 1992.
27. Beasley R, Smith DA, McHaffie DJ. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation BMJ. 1985;290 9-11.
28. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation. Br Heart J 1990;63.225-227
29. Platia EV, Michelson EL, Portefield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 1989,63 925-929.
30. Shenasa M, Kus T, Fromer M, LeBlanc RA, Dubuc M, Nadeau R Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation. Am J Cardiol 1988,62 403-407.
31. David D, Segni ED, Klein HO, Kaplinsky E Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation Am J Cardiol. 1979,44.1378-1382.
32. Pritchett ELC Management of atrial fibrillation. N Engl J Med 1992;326:1264-1271.
33. Coplen SE, Antmann EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion Circulation 1990,82:1106-1116.
34. Suttorp MJ, Kingma JH, Jessurun ER, Lie-A-Huen L, von Hemel NM, Lie KI The value of class Ic antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or atrial flutter to sinus rhythm J Am Coll Cardiol. 1990,16 1772-1777.
35. Suttorp MJ, Kingma JH, Lie-A-Huen L, Mast EG Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol. 1989,63:693-696.
36. Chu-Pak L, Wing-Hung L, Cheuk-Kit W A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. Am Heart J. 1992;124:645-650
37. Noc M, Stajer D, Horvat NI. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol. 1990;65:679-680.
38. Vitolo E, Tronci M Larovere MT, Rumolo R, Morabito A Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol. 1981;36 431-444.
39. Horowitz LN, Spielman SR, Greenspan AM, et al. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985;6:1402-1407.
40. Reimold SC, Cantillon CO, Friedman PL, Antman EM Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1993,71:558-563.
41. Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL Therapy of refractory atrial fibrillation and atrial flutter J Am Coll Cardiol. 1990; 15:698-707.
42. Williamson BD, Man KC, Daoud E, Niebauer M, Strickberger SA, Morady F. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation N Engl J Med. 1994,331 910-917.
43. Ezekowitz MD, Bridgers SL, James KE, et al Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992, 327.1406-1412
44. Petersen P, Godtfredson J, Boysen G, Andersen E, Andersen B Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK Study. Lancet 1989;1: 175-179.
45. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18 349-355.
46. Stroke Prevention in Atrial Fibrillation Investigators Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study Lancet. 1994,343:687-691
47. Roy D, Marchand E, Gagne P, Chabot M, Cartier R Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J. 1986.112:1039-1043
48. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attacks or minor stroke. Lancet 1993;342:1255-1262.
49. Atwood JE, Albers GW. Anticoagulation and atrial fibrillation Herz 1993 18 27-38
50. Laupacis A, Albers G, Dunn M, Feinberg W Antithrombotic therapy in atrial fibrillation. Chest. 1992;102(suppl 4):426S-433S.
51. The Second Report of the Cerebral Embolism Task Force. Cardiogenic brain embolism. Arch Neurol 1989;46:727-743
52. Pietersen AH, Hellemann H. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Am J Cardiol 1991,67:713-717.
53. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med 1994;154 1443-1448.
54. Albers GW, Atwood JE, Hirsh J, Sherman DG, Hughes KA, Connolly ST. Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med. 1991; 115.727-736
55. Onundarson PT, Thorgeirsson G, Jonmundsson E, Sigfusson N, Hardarson T. Chronic atrial fibrillation: epidemiologic features and 14-year follow-up Eur Heart J. 1987;8:521-527